Synopsis: Biocon Ltd. shares rose nearly 7% after a ₹3,680 crore block deal saw 9.2 crore shares (5.64% stake) change hands at ₹400 per share. The transaction is believed to mark Viatris-owned Mylan’s complete exit from the company.
The shares of the Mid-cap stock specialising in the development, manufacturing, and commercialization of affordable biopharmaceuticals have been in the spotlight in today’s trade after equity worth Rs. 3,680 crore changed hands in a block window deal
With a market capitalization of Rs. 71,003.86 crores on the day’s trade, the shares of Biocon Ltd jumped upto 7 percent, making a high of Rs. 439.35 per share compared to its previous day’s close price of Rs. 410.55 per share.
What Happened
Biocon Ltd. shares worth Rs. 3,680 crore changed hands in the pre-open block deal window on Tuesday, July 14, according to the latest exchange data. A total of 9.2 crore shares, representing 5.64% of the company’s outstanding equity, were traded in the transaction. The block deal was executed at an average price of Rs. 400 per share. The identities of the buyers and sellers have not yet been officially disclosed.
The block deal follows reports that Viatris-owned Mylan was looking to exit its entire stake in Biocon. Mylan had received the stake through a preferential allotment after Biocon acquired Viatris’ stake in Biocon Biologics in January 2026 via a combination of a share swap and cash consideration. The completion of the stake sale removes a key overhang on the stock, leading to a positive market reaction.
At the end of the March quarter, Biocon’s promoters held a 44.68% stake, while mutual funds owned 15.49% and foreign portfolio investors held 8.16%. The successful completion of the large block deal is expected to improve investor sentiment by clearing uncertainty around Mylan’s planned exit.
Financials & Others
The company’s revenue rose by 2.25 percent from Rs. 4,417 crores in Q4FY25 to Rs. 4,517 crores in Q4FY26. Meanwhile, Net profit declined from Rs. 459 crores to Rs. 199 crores during the same period.
It has relatively weak profitability, with a ROCE of 3.75% and ROE of 1.40%, indicating modest returns on capital and shareholders’ equity. It also has a debt-to-equity ratio of 0.45, reflecting a moderate level of leverage.
Biocon Limited is a leading global biopharmaceutical company headquartered in Bengaluru, India. The company is engaged in developing, manufacturing, and commercializing biosimilars, generic medicines, and specialty products for patients worldwide.
It focuses on key therapeutic areas such as diabetes, oncology, immunology, cardiovascular diseases, and ophthalmology. With strong research capabilities and global manufacturing facilities, Biocon aims to make high-quality and affordable medicines accessible to patients across the world.
Biocon Group is a leading global biopharmaceutical company with a 47+ year legacy, serving patients in 120+ countries. With a market capitalisation of $7.4 billion, the company focuses on improving lives by delivering affordable healthcare products and differentiated services worldwide.
The company operates 11 manufacturing facilities, has secured 215+ cGMP approvals, and holds 1,500+ patents. Its services are trusted by 16 of the world’s top 20 pharmaceutical companies, highlighting its strong global presence and manufacturing capabilities.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
